SOPA Images via Getty Images
CORONAVIRUS – The French anti-Covid vaccine is not about to see the light of day. After abandoning his vaccine project at Messenger RNA, the other vaccine candidate against the Covid-19 from the laboratory Sanofi is late. Initially expected by the end of the year, the final results of its clinical trial should finally be published in the first quarter of 2022.
Sanofi’s vaccine will therefore be lagging behind the schedule for the vaccine booster, while the appointment to perform a third dose are stormed. Olivier Véran announced the goal 20 million booster doses injected by December 25.
The group, which is developing this recombinant protein-based vaccine with the British GSK, unveiled interim results deemed positive as a booster dose on Wednesday, December 15, but it does not give a precise timetable for its marketing.
Promising results
“We will bring this vaccine next year. If it is for a third dose, it will be a third dose, ”Olivier Bogillot, France president of Sanofi, told AFP on Wednesday. “We are no longer in a race for speed. (…) We can see that the virus is here for a long time. We will have a French vaccine, ”he continued.
A single booster dose of the vaccine candidate from Sanofi and GSK “made it possible to obtain strong immune responses”, argues the laboratory in a press release. The results of this test indeed show a multiplication of the order of 9 to 43 in neutralizing antibodies, regardless of the vaccine received as a primary vaccination.
In addition, the global phase 3 trial, in primary vaccination, is continuing, according to the recommendation of the Independent Committee for Surveillance and Data Monitoring, until early 2022, in order to collect more data.
Sanofi criticized against its competitors Pfizer-BioNTech and Moderna
The juggernaut is expected, while the France has so far failed to market a vaccine against Covid-19. After an initial period of 6 months, the group had counted on the final results of the clinical trial at the end of 2021, for marketing in early 2022.
Sanofi, one of the world leaders in non-Covid vaccines, has been widely criticized against its competitors Pfizer-BioNTech and Moderna, which launched their vaccine using messenger RNA technology as early as December 2020.
But Sanofi opted for a different technology, with a recombinant protein vaccine, which uses the spike protein of the SARS-CoV-2 virus as an antigen to help the body recognize the virus.
Sanofi was also developing another vaccine, messenger RNA, which it nevertheless decided to abandon at the end of September, judging that it would arrive too late for the pandemic.
See also on The HuffPost: Will there be more recalls against the Covid-19?
https://wakelet.com/wake/FcQXS_EnxgIk4cr-yG25L
https://wakelet.com/wake/-b3Ork2vJDHJzaKDxKySz
https://wakelet.com/wake/K6YT9-6nqrUUrzUDCdp1P
https://wakelet.com/wake/xJgbjA1PsubePzL6zYbQw
https://peatix.com/user/9045224
https://wakelet.com/wake/DWy5z-m2c1nME6pdnl2Jj
https://peatix.com/user/9184591
https://wakelet.com/wake/afh6gI4QvOS0_t1yqwXlz
https://peatix.com/user/9073709
https://wakelet.com/wake/iobofeVjrn8yi_yxwdq4q
https://peatix.com/user/8838644
https://wakelet.com/wake/OO56PzYt8wpf7uKukzRIH
https://wakelet.com/wake/FrvweitaNRkhdx50O1IqC
https://wakelet.com/wake/qsy4tmMA_g6AVcRpqjS6f
https://peatix.com/user/9186827
https://wakelet.com/wake/ccjBn_aaixKSaLXlkfRkP
https://wakelet.com/wake/4zfj9AhkAU4BNrS5hw0Wy
https://wakelet.com/wake/bUsiZEckIoX3Tv294ePXx
https://wakelet.com/wake/TETGfoPnluF5TG7i9PQSA
https://peatix.com/user/9045132
https://wakelet.com/wake/sFcUhwOKUloneKyXalqar
https://peatix.com/user/9062374
https://wakelet.com/wake/9gSKq43lF0m4FXwPniZ1U
https://peatix.com/user/9073474
https://wakelet.com/wake/IEDMD3E4xA5_W15SXf7Ar